Skip to main content
. Author manuscript; available in PMC: 2017 Apr 1.
Published in final edited form as: Cancer Immunol Res. 2016 Feb 15;4(4):354–365. doi: 10.1158/2326-6066.CIR-15-0241

Figure 6. Mutated KRAS led to the secretion of IL10 and TGFβ1.

Figure 6

Silencing KRAS resulted in a significant reduction of (A) IL10 and TGFβ1 mRNA expression and (B) IL10 and TGFβ1 secretion from mutated KRAS tumor cells (SW620). (C) Overexpression of mutant KRAS in wild-type KRAS (Colo320) resulted in a significant increase in IL10 and TGFβ1 mRNA. Data are means ± s.d. from three independent experiments, *P < 0.05, ** P < 0.005.